

Supporting Information

Preparation of the Key Dolutegravir Intermediate via MgBr₂-Promoted Cyclization

Jiahui Kong ^{1,2}, Haijian Xia ², Renbao He ², Hao Chen ² and Yongping Yu ^{1,*}

¹ Zhejiang Province Key Laboratory of Anti-Cancer Drug Research, College of Pharmaceutical Science, Zhejiang University, Hangzhou 310058, China; jiahui.kong@yongtaitech.com (J.K.)

² Zhejiang Yongtai Technology Co. Ltd., Taizhou 317016, China; haijian.xia@yongtaitech.com (H.X.); renbao.he@yongtaitech.com (R.H.); a_chenhaoHao@126.com (H.C.)

* Correspondence: yyu@zju.edu.cn




Figure S1. ¹H NMR spectra of P3 in CDCl₃.




Figure S2. ¹³C NMR spectra of P3 in CDCl₃.




Figure S3. LCMS of P3.




Figure S4. ¹H NMR spectra of P4 in CDCl₃.




Figure S5. ¹³CNMR spectra of P4 in CDCl₃.




Figure S6. LCMS of P4.




Figure S7. ¹H NMR spectra of P6 in CDCl₃.




Figure S8. ¹³C NMR spectra of P6 in CDCl₃.




Figure S9. LCMS of P6.




Figure S10. ¹H NMR spectra of 1 in CDCl₃.




Figure S11. ¹³CNMR spectra of 1 in CDCl₃.




Figure S12. LCMS of 1.




Figure S13. LCMS of P6-isos